Marrow function reconstitution by fraction 3 of Percoll-density-gradient-separated cells.

Area of Science:

• Hematology
• Oncology
• Biotechnology

Background:

• High-dose chemotherapy and melphalan require autologous marrow rescue.
• Standard marrow rescue uses whole buffy coats, which are large volume.
• Optimizing marrow stem cell collection and reinfusion is crucial for patient recovery.

Purpose of the Study:

• To evaluate the efficacy of fraction 3 from Percoll-separated bone marrow for autologous rescue.
• To assess the hematopoietic recovery time and stem cell yield using this fraction.
• To determine if this method is suitable for pediatric patients with advanced cancers or leukemia.

Main Methods:

• Eight pediatric patients with advanced tumors or acute myeloid leukemia received fraction 3 from Percoll-gradient separated bone marrow buffy coats.
• Patients underwent very-high-dose chemotherapy or marrow ablative high-dose melphalan.
• Hematopoietic reconstitution was assessed by neutrophil and platelet counts.

Main Results:

• Fraction 3 yielded a comparable number of CFU-c (colony-forming units-culture) to whole buffy coats.
• Seven out of eight patients showed prompt marrow reconstitution (neutrophils >0.5 X 10(9)/L, platelets >50 X 10(9)/L) within 15-16 days.
• One patient experienced delayed hematopoietic recovery, indicating potential variability in fraction effectiveness.

Conclusions:

• Fraction 3 from Percoll-separated marrow is a viable option for autologous marrow rescue.
• This method provides a small-volume product with good stem cell recovery.
• It can effectively reconstitute marrow function in the majority of pediatric patients treated with intensive chemotherapy regimens.